The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
Approval Alert | Nirogacestat in Desmoid Tumors
Patients with desmoid tumors can now receive nirogacestat following the FDA’s approval of the agent.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
3
FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma
4
Should Those with Non-Hodgkin Lymphoma Receive CAR T or Bispecifics?
5
